Thompson Siegel & Walmsley LLC Acquires 2,871 Shares of Amgen Inc. (NASDAQ:AMGN)

Thompson Siegel & Walmsley LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 41,548 shares of the medical research company's stock after buying an additional 2,871 shares during the period. Thompson Siegel & Walmsley LLC's holdings in Amgen were worth $13,387,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Meyer Handelman Co. raised its position in shares of Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company's stock valued at $40,566,000 after purchasing an additional 8,700 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Amgen by 0.3% in the 3rd quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after purchasing an additional 5,500 shares during the last quarter. Napa Wealth Management bought a new position in Amgen during the 3rd quarter worth $1,104,000. First Horizon Advisors Inc. increased its position in Amgen by 3.2% in the third quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company's stock worth $19,581,000 after buying an additional 1,872 shares during the period. Finally, Second Half Financial Partners LLC acquired a new position in shares of Amgen during the third quarter valued at $3,413,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of Amgen stock traded up $2.41 during trading on Friday, reaching $292.31. The company's stock had a trading volume of 485,084 shares, compared to its average volume of 2,466,125. Amgen Inc. has a one year low of $260.68 and a one year high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm has a market cap of $157.13 billion, a price-to-earnings ratio of 37.10, a price-to-earnings-growth ratio of 2.50 and a beta of 0.60. The business's fifty day moving average price is $317.28 and its 200-day moving average price is $318.02.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the business earned $4.96 earnings per share. As a group, equities research analysts predict that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.08%. Amgen's payout ratio is 115.24%.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Oppenheimer reiterated an "outperform" rating and set a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Truist Financial lowered Amgen from a "buy" rating to a "hold" rating and boosted their price target for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Finally, Citigroup started coverage on Amgen in a report on Thursday, November 14th. They set a "neutral" rating and a $335.00 price target on the stock. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.